Cancer clinical trials in the region Grand Est
291 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT07106632
#2024-519655-28-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
24 recruiting sites
UNICANCER
Phase 3
Lung cancer
#NCT07361510
#2025-523586-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bristol-Myers Squibb
Phase 3
Skin cancer
#NCT06692556
Required histologic types
Squamous cell carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Radiotherapy
12 recruiting sites
Centre Léon Bérard
Phase 3
Breast cancer
#NCT06103864
#2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
8 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT06103864
#2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
#NCT07228832
#2025-521587-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
9 recruiting sites
Summit Therapeutics
Phase 3
Acute leukemia
#NCT07211958
#2025-522279-27-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
5 recruiting sites
Syndax Pharmaceuticals
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT06104566
#2023-508005-24-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Liver and bile duct cancer
#NCT07221253
#2025-523085-24-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
AstraZeneca
Phase 3
Brain tumors / Central nervous system tumors
#NCT05512403
#2022-501688-42-00
Required histologic types
Gliomas
Required histologic sub types
Low-grade glioma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
1 recruiting site
Hôpital central, Nancy, France